利伐沙班用于肾病综合征预防性抗凝治疗的疗效及安全性评价

Evaluation of the efficacy and safety of rivaroxaban in prophylactic anticoagulant therapy for nephrotic syndrome

关键词:  利伐沙班  肾病综合征  预防性抗凝治疗  疗效  安全性

Key words:  rivaroxaban  nephrotic syndrome  prophylactic anticoagulant therapy  therapeutic effect  safety

摘要:

目的 探讨利伐沙班在肾病综合征( Nephrotic Syndrome，NS)预防性抗凝治疗中的疗效及安全性。方法 收集2021年10月到2025年6月我院肾脏内科诊断为NS的患者资料，设定纳入和排除标准，筛选后根据患者是否预防性使用抗凝药物及抗凝药物的种类分组，分为利伐沙班组（37例）、华法林组（29例）、未抗凝组（32例），对三组治疗前基本情况进行统计分析，并对三组患者用药后6个月内的血栓事件及出血事件进行统计和分析。结果 利伐沙班组与华法林组治疗后新发血栓发生率无显著性差异（P>0.05），而利伐沙班组与未抗凝组相比，新发血栓发生率存在显著性差异（P<0.05），利伐沙班组新发血栓事件较未抗凝组明显减少。利伐沙班组发生出血事件2例，华法林组发生出血事件5例，未抗凝组发生出血事件1例，三组出血发生率比较无显著性差异（P＞0.05）。结论 本研究表明，利伐沙班在NS患者的预防抗凝治疗中具有一定的有效性和安全性。

Abstract:

OBJECTIVE to investigate the efficacy and safety of rivaroxaban in prophylactic anticoagulation therapy of Nephrotic Syndrome (NS). METHODS The data of patients diagnosed with nephrotic syndrome in the Department of Nephrology of our hospital from October 2021 to June 2025 were collected, and the inclusion and exclusion criteria were set. After screening, and then group them based on whether they used anticoagulant medications prophylactically and the type of anticoagulant medication used. they were divided into rivaroxaban group (37 cases), warfarin group (29 cases), and non-anticoagulation group (32 cases). The basic conditions before treatment of the three groups were statistically analyzed, and the incidence of thrombosis and bleeding in the three groups 6 months after medication. RESULTS There was no significant difference in the incidence of new thrombosis between the rivaroxaban group and the warfarin group after treatment (P > 0.05), while there was a significant difference in the incidence of new thrombosis between the rivaroxaban group and the non-anticoagulated group (P < 0.05), the new thrombotic events in the rivaroxaban group were significantly reduced compared with the non-anticoagulated group. There were two bleeding events in the rivaroxaban group, There were five bleeding events in the warfarin group; One case of bleeding occurred in the group without anticoagulation. There was no significant difference in the incidence of bleeding between the three groups (P > 0.05). CONCLUSION This study shows that rivaroxaban has certain effectiveness and safety in the prevention and anticoagulation therapy of patients with nephrotic syndrome (NS).